What are the current hypertension management guidelines for adults, including blood pressure targets, lifestyle modifications, and first‑line pharmacologic therapy?

Hypertension Management Guidelines for Adults

For adults with confirmed hypertension (BP ≥140/90 mmHg), initiate both lifestyle modifications and pharmacological therapy simultaneously, targeting a blood pressure goal of <130/80 mmHg in most patients, with first-line drug therapy consisting of thiazide/thiazide-like diuretics, ACE inhibitors/ARBs, or long-acting dihydropyridine calcium channel blockers. 1

Diagnosis and Confirmation

Blood Pressure Measurement:

• Use validated automated upper arm cuff devices with appropriate cuff size 1
• Measure BP in both arms simultaneously at first visit; use the arm with higher readings for subsequent measurements 1
• Office BP ≥140/90 mmHg requires confirmation with out-of-office monitoring 1
• Confirm hypertension with home BP ≥135/85 mmHg or 24-hour ambulatory BP ≥130/80 mmHg 1

Blood Pressure Categories:

• Normal: <130/85 mmHg 1
• Elevated/High-normal: 130-139/85-89 mmHg 1
• Grade 1 Hypertension: 140-159/90-99 mmHg 1
• Grade 2 Hypertension: ≥160/100 mmHg 1

Treatment Initiation Thresholds

Immediate Pharmacological Treatment:

• All patients with BP ≥140/90 mmHg (strong recommendation) 1
• Patients with existing CVD and BP 130-139 mmHg (strong recommendation) 1
• High-risk patients (CVD, CKD, diabetes, organ damage, or aged 50-80 years) with BP 140-159/90-99 mmHg 1

Consider Pharmacological Treatment:

• Patients without CVD but with high cardiovascular risk, diabetes, or CKD and BP 130-139 mmHg (conditional recommendation) 1
• After 3-6 months of lifestyle intervention in low-moderate risk patients with persistent BP 140-159/90-99 mmHg 1

Lifestyle Modifications

All patients require lifestyle interventions, which should be initiated concurrently with pharmacological therapy in confirmed hypertension: 1, 2

• Weight loss: Achieve and maintain healthy body weight 2
• Dietary sodium reduction: Low sodium intake (<2g/day sodium) 2
• Potassium supplementation: High potassium intake through diet 2
• Healthy dietary pattern: DASH diet or Mediterranean diet 2
• Physical activity: Regular aerobic exercise 2
• Alcohol moderation: Limit or eliminate alcohol consumption 2

The BP-lowering effects of individual lifestyle components are partially additive and enhance pharmacological therapy efficacy 2

First-Line Pharmacological Therapy

Drug Classes (Strong Recommendation):

The WHO and ISH recommend any of these four classes as first-line agents 1:

1. Thiazide and thiazide-like diuretics (chlorthalidone preferred over hydrochlorothiazide) 1
2. ACE inhibitors 1
3. Angiotensin receptor blockers (ARBs) 1
4. Long-acting dihydropyridine calcium channel blockers (amlodipine preferred) 1

Race-Based Treatment Algorithm:

Non-Black Patients: 1

1. Start low-dose ACE inhibitor or ARB
2. Increase to full dose
3. Add thiazide/thiazide-like diuretic
4. Add spironolactone (or if not tolerated: amiloride, doxazosin, eplerenone, clonidine, or beta-blocker)

Black Patients: 1

1. Start low-dose ARB + DHP-CCB or DHP-CCB + thiazide/thiazide-like diuretic
2. Increase to full dose
3. Add diuretic or ACE inhibitor/ARB
4. Add spironolactone (or if not tolerated: amiloride, doxazosin, eplerenone, clonidine, or beta-blocker)

Combination Therapy:

• Single-pill combinations are preferred to improve adherence and persistence (conditional recommendation) 1
• Most patients require combination therapy for adequate BP control 1, 3
• Consider monotherapy only in low-risk grade 1 hypertension and patients aged >80 years or frail 1
• Use once-daily dosing when possible 1

Blood Pressure Targets

Primary Target:

• <130/80 mmHg for most adults (ISH 2020 target) 1
• <140/90 mmHg minimum target (WHO strong recommendation) 1

Specific Populations:

• Patients with known CVD: SBP <130 mmHg (strong recommendation) 1
• High-risk patients (high CVD risk, diabetes, CKD): SBP <130 mmHg (conditional recommendation) 1
• Elderly patients: Individualize based on frailty; SBP 130-139 mmHg if aged ≥65 years and tolerated 1
• Patients aged >80 years or frail: Individualize targets, consider higher targets 1

The 2024 ESC guidelines recommend a target SBP of 120-129 mmHg with individualized goals for frailty or age ≥85 years 1, 4

Monitoring and Follow-Up

Achievement Timeline:

• Achieve BP control within 3 months of initiating therapy 1
• Monthly follow-up after initiation or medication changes until target reached (conditional recommendation) 1

Maintenance Monitoring:

• Follow-up every 3-5 months for patients under control (conditional recommendation) 1
• Use home BP monitoring for medication titration 1
• Replace 30-day with 90-day refills when allowed 1

Laboratory Testing:

• Obtain tests to screen for comorbidities when starting therapy, but only when testing does not delay treatment (conditional recommendation) 1
• Screen for secondary hypertension and organ damage as indicated 1
• Check medication adherence regularly 1

Common Pitfalls and Caveats

Avoid These Errors:

• Do not delay pharmacological treatment in confirmed hypertension (BP ≥140/90 mmHg) while attempting lifestyle modifications alone 1
• Do not use hydrochlorothiazide when chlorthalidone is available; chlorthalidone has superior outcomes data 1
• Do not accept suboptimal diuretic dosing in combination pills 1
• Do not withhold intensive BP control due to concerns about orthostatic hypotension; asymptomatic orthostatic hypotension is not associated with increased adverse events 1

Resistant Hypertension:

• Defined as BP ≥130/80 mmHg on ≥3 antihypertensive medications at maximum tolerated doses, or BP <130/80 mmHg requiring ≥4 drugs 1
• Exclude pseudo-resistance: inaccurate BP measurement, white coat effect, suboptimal adherence 1
• Add spironolactone as fourth-line agent 1
• Refer to hypertension specialist if BP remains uncontrolled 1

Special Considerations:

• Intensive BP lowering may prevent or arrest cognitive decline in older adults 1
• Team-based care and telemonitoring are most effective for achieving BP control 1
• CVD risk assessment should not delay treatment initiation but can guide decisions for BP 130-139 mmHg 1